Apabetalone for Pulmonary Arterial Hypertension: a Pilot Study

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

August 22, 2019

Primary Completion Date

October 15, 2021

Study Completion Date

December 13, 2021

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

Apabetalone

A 4-week pre-treatment phase will allow ensuring that patients are on stable doses of medication. Patients will be given doses of apabetalone 100mg BID for 16 weeks. Patients will be regularly followed (Fig.1). At baseline and week 16, a cardiac catheterization and MRI will assess changes in pulmonary hemodynamics and RV function.

Trial Locations (2)

T1Y 6J4

Peter Lougheed Center, Calgary

G1V 4G5

IUCPQ-UL, Québec

All Listed Sponsors
collaborator

Resverlogix Corp

INDUSTRY

lead

Steeve Provencher

OTHER

NCT03655704 - Apabetalone for Pulmonary Arterial Hypertension: a Pilot Study | Biotech Hunter | Biotech Hunter